CNS5:Medulloblastoma, WNT-activated: Difference between revisions
| [checked revision] | [checked revision] |
No edit summary |
Bailey.Glen (talk | contribs) No edit summary |
||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:Medulloblastoma, WNT-activated}} | {{DISPLAYTITLE:Medulloblastoma, WNT-activated}} | ||
[[CNS5:Table_of_Contents|Central Nervous System Tumours(WHO Classification, 5th ed.)]] | [[CNS5:Table_of_Contents|Central Nervous System Tumours (WHO Classification, 5th ed.)]] | ||
{{Under Construction}} | {{Under Construction}} | ||
| Line 33: | Line 33: | ||
|} | |} | ||
==Related Terminology== | ==Related Terminology== | ||
{| class="wikitable" | {| class="wikitable" | ||
|+ | |+ | ||
|Acceptable | |Acceptable | ||
| | |N/A | ||
|- | |- | ||
|Not Recommended | |Not Recommended | ||
| | |N/A | ||
|} | |} | ||
| Line 160: | Line 146: | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
|- | |- | ||
!Chr #!! | !Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s) | ||
! | !Diagnostic, Prognostic, and Therapeutic Significance - D, P, T | ||
! | !Established Clinical Significance Per Guidelines - Yes or No (Source) | ||
! | !Clinical Relevance Details/Other Notes | ||
|- | |- | ||
|<span class="blue-text">EXAMPLE:</span> | |<span class="blue-text">EXAMPLE:</span> | ||
| Line 251: | Line 237: | ||
!Chromosomal Pattern | !Chromosomal Pattern | ||
!Molecular Pathogenesis | !Molecular Pathogenesis | ||
! | !Prevalence - | ||
Common >20%, Recurrent 5-20% or Rare <5% (Disease) | |||
! | !Diagnostic, Prognostic, and Therapeutic Significance - D, P, T | ||
! | !Established Clinical Significance Per Guidelines - Yes or No (Source) | ||
! | !Clinical Relevance Details/Other Notes | ||
|- | |- | ||
| | | | ||
| Line 268: | Line 254: | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
|- | |- | ||
!Gene!! | !Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence - | ||
Common >20%, Recurrent 5-20% or Rare <5% (Disease) | |||
! | !Diagnostic, Prognostic, and Therapeutic Significance - D, P, T | ||
! | !Established Clinical Significance Per Guidelines - Yes or No (Source) | ||
! | !Clinical Relevance Details/Other Notes | ||
|- | |- | ||
|<span class="blue-text">EXAMPLE:</span>''EGFR'' | |<span class="blue-text">EXAMPLE:</span>''EGFR'' | ||
| Line 320: | Line 306: | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
|- | |- | ||
!Gene; Genetic Alteration!! | !Gene; Genetic Alteration!!Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other)!!Prevalence (COSMIC / TCGA / Other)!!Concomitant Mutations!!Mutually Exclusive Mutations | ||
! | !Diagnostic Significance (Yes, No or Unknown) | ||
!Prognostic Significance (Yes, No or Unknown) | !Prognostic Significance (Yes, No or Unknown) | ||
!Therapeutic Significance (Yes, No or Unknown) | !Therapeutic Significance (Yes, No or Unknown) | ||
| Line 332: | Line 318: | ||
|''APC'' | |''APC'' | ||
|Yes | |Yes | ||
|Yes – Favorable prognosis<ref name=":3">{{Cite journal|last=Surun|first=Aurore|last2=Varlet|first2=Pascale|last3=Brugières|first3=Laurence|last4=Lacour|first4=Brigitte|last5=Faure-Conter|first5=Cécile|last6=Leblond|first6=Pierre|last7=Bertozzi-Salomon|first7=Anne-Isabelle|last8=Berger|first8=Claire|last9=André|first9=Nicolas|date=2020-01-11|title=Medulloblastomas associated with an APC germline pathogenic variant share the good prognosis of CTNNB1-mutated medulloblastomas|url=https://pubmed.ncbi.nlm.nih.gov/31504825|journal=Neuro-Oncology|volume=22|issue=1|pages=128–138|doi=10.1093/neuonc/noz154|issn=1523-5866|pmc=6954432|pmid=31504825}}</ref> | |Yes – Favorable prognosis<ref name=":3">{{Cite journal|last=Surun|first=Aurore|last2=Varlet|first2=Pascale|last3=Brugières|first3=Laurence|last4=Lacour|first4=Brigitte|last5=Faure-Conter|first5=Cécile|last6=Leblond|first6=Pierre|last7=Bertozzi-Salomon|first7=Anne-Isabelle|last8=Berger|first8=Claire|last9=André|first9=Nicolas|date=2020-01-11|title=Medulloblastomas associated with an APC germline pathogenic variant share the good prognosis of CTNNB1-mutated medulloblastomas|url=https://pubmed.ncbi.nlm.nih.gov/31504825|journal=Neuro-Oncology|volume=22|issue=1|pages=128–138|doi=10.1093/neuonc/noz154|issn=1523-5866|pmc=6954432|pmid=31504825}}</ref> | ||
|No | |No | ||
|~85% of cases<ref name=":1" />; Somatic | |~85% of cases<ref name=":1" />; Somatic | ||